APA (7th ed.) Citation

B, B., H, H., RB, M., J, F., U, C., BM, B., . . . G, P. (2022). Extended-Duration Low-Intensity Apixaban to Prevent Recurrence in Patients with Provoked Venous Thromboembolism and Enduring Risk Factors: Rationale and Design of the HI-PRO Trial. Thrombosis and haemostasis, 122(6), 1061. https://doi.org/10.1055/a-1646-2244

Chicago Style (17th ed.) Citation

B, Bikdeli, et al. "Extended-Duration Low-Intensity Apixaban to Prevent Recurrence in Patients with Provoked Venous Thromboembolism and Enduring Risk Factors: Rationale and Design of the HI-PRO Trial." Thrombosis and Haemostasis 122, no. 6 (2022): 1061. https://doi.org/10.1055/a-1646-2244.

MLA (9th ed.) Citation

B, Bikdeli, et al. "Extended-Duration Low-Intensity Apixaban to Prevent Recurrence in Patients with Provoked Venous Thromboembolism and Enduring Risk Factors: Rationale and Design of the HI-PRO Trial." Thrombosis and Haemostasis, vol. 122, no. 6, 2022, p. 1061, https://doi.org/10.1055/a-1646-2244.